GRAL
GRAIL, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$122.42
+3.91%Price chart
Sep 17Sep 22Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$117.68
From 52W high−20.55%
Volume570925.00
Market cap$5.47B
P/E (TTM)—
P/S (TTM)33.1x
Div yield—
Key dataOct 19, 2026
Open
$117.68
From 52W high
−20.55%
Volume
570925.00
Market cap
$5.47B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.6x
P/E (TTM)
—
RSI (14)
52.1
MomentumView details →
1D Return
+3.91%
YTD Return
+44.20%
SummaryUpdated Jun 1, 2026
GRAIL, Inc. (NASDAQ:GRAL) is a biotechnology company founded in 2015 and headquartered in Menlo Park, California. The company was spun off from genomics giant Illumina, Inc. and began trading publicly in June 2024 following regulatory pressure from European authorities. GRAIL specializes in developing multi-cancer early detection (MCED) technology, with its flagship product being the Galleri blood test that can screen for over 50 types of cancer in asymptomatic individuals. The company represents a pioneering effort in liquid biopsy technology, aiming to revolutionize cancer screening by detecting circulating tumor DNA in blood samples before traditional imaging or symptoms appear.
Similar companies
Latest newsMore news →
The FDA advisory panel voted 7-2, with one abstention, that GRAIL, Inc.’s Galleri blood test offers more potential benefits than risks; the FDA is not bound by the recommendation.14d agoGRAIL, Inc. announced it will present new data from the NHS-Galleri trial and the PATHFINDER 2 study evaluating its Galleri multi-cancer early detection test at the EDCC in Edinburgh and the ESMO Congress 2026 in Madrid.14d agoAn FDA advisory committee met to vote on whether the agency should approve Grail's Galleri multi-cancer blood test.27d ago